| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/06/1992 | WO1992001783A1 Dna capable of site-specific integration into mycobacteria |
| 02/06/1992 | WO1992001718A2 Functionally active selectin-derived peptides and ligand for gmp-140 |
| 02/06/1992 | WO1992001717A1 Bacterial stress proteins |
| 02/06/1992 | WO1992001714A1 Non-a non-b hepatitis virus antigen |
| 02/06/1992 | WO1992001713A1 Peptides and analogues and mixtures thereof for detecting antibodies to htlv-i and htlv-ii viruses |
| 02/06/1992 | WO1992001705A1 Plasmodium vivax and plasmodium knowlesi duffy receptor |
| 02/06/1992 | WO1992001473A1 Improved immunotherapeutic method of preventing or treating viral respiratory tract disease |
| 02/06/1992 | WO1992001471A1 Methods of use of bovine respiratory syncytial virus recombinant dna, proteins vaccines, antibodies, and transformed cells |
| 02/06/1992 | WO1992001470A1 Target specific antibody-superantigen conjugates and their preparation |
| 02/06/1992 | WO1992001460A1 Antigenic iron repressible proteins from n. meningitidis related to the hemolysin family of toxins |
| 02/06/1992 | WO1992001459A1 Adoptive immunotherapy with interleukin-7 |
| 02/06/1992 | WO1992000323A3 Human cytomegalovirus (hcmv) antigen pp150 |
| 02/06/1992 | CA2087853A1 Methods of use of bovine respiratory syncytial virus recombinant dna, proteins vaccines, antibodies, and transformed cells |
| 02/06/1992 | CA2087160A1 Antigenic iron repressible proteins from n. meningitidis related to the hemolysin family of toxins |
| 02/06/1992 | CA2087100A1 Immunotherapeutic method of preventing or treating viral respiratory tract disease |
| 02/05/1992 | EP0469359A2 Method and product for the treatment of gastric disease |
| 02/05/1992 | EP0469281A1 Amino acid residue sequence of hepatitis B core antigen |
| 02/05/1992 | EP0469089A1 Generation of hybrid genes and proteins by virus-mediated recombination |
| 02/05/1992 | EP0193585B1 Cross-reactive and protective epitopes of circumsporozoite proteins |
| 02/05/1992 | EP0191772B1 Acid-cleavable compound |
| 02/04/1992 | US5085862 Mutants, vaccine; immunoprotective in mice |
| 02/03/1992 | WO1992002817A1 Adhesion receptors for pathogenic or opportunistic microorganisms |
| 02/03/1992 | WO1992002628A1 Expression of human cmv glycoprotein-h using the baculovirus-insect cell expression system |
| 02/03/1992 | WO1992002251A1 Herpes simplex virus vp16 vaccines |
| 02/03/1992 | CA2088599A1 Expression of human cmv glycoprotein-h using the baculovirus-insect cell expression system |
| 02/01/1992 | CA2048029A1 Amino acid residue sequence of hepatitis b core antigen |
| 01/30/1992 | DE4107765A1 Pankreas-elastase-1-spezifischer antikoerper, ein verfahren zu seiner gewinnung und ein testkit der solche antikoerper enthaelt Pancreatic elastase-1-specific antibodies, a process for its production and to a test kit which such antibody contains |
| 01/30/1992 | DE4023721A1 Modified Gram negative bacteria for use as vaccine and adjuvant - are transformed to express lytic protein or toxin, forming ghost(s) which present many cell wall epitope(s) |
| 01/29/1992 | WO1992002630A1 Pancreas-elastasis-1-specific antibody, a process for obtaining it and a test kit containing such antibodies |
| 01/29/1992 | EP0468714A2 Peptide-polysaccharide-protein conjugate vaccines |
| 01/29/1992 | EP0468702A2 Novel process for purification of Hepatitis-A virus capsids |
| 01/29/1992 | EP0468637A1 In vivo targeting with bifunctional antibodies |
| 01/29/1992 | EP0468601A1 Methods and materials for HIV detection and therapy |
| 01/29/1992 | EP0468527A2 Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and prevention thereof as vaccines |
| 01/29/1992 | EP0468441A1 Use of particular compounds for manufacture of pharmaceutical formulations for metabolic treatments |
| 01/29/1992 | EP0468049A1 Monoclonal antibodies for recognizing a peptide linked to a major histocompatibility antigen |
| 01/29/1992 | EP0467972A1 Rickettsial antigens for vaccination and diagnosis |
| 01/29/1992 | EP0467965A1 Plasmodium circumsporozoite protein analogs lacking repeat sequences |
| 01/29/1992 | EP0467932A1 Urokinase-type plasminogen activator receptor |
| 01/28/1992 | WO1992002542A1 Peptides and pharmaceutical compositions having glycoprotein hormone agonistic or antagonistic activity |
| 01/28/1992 | US5084559 Protein a domain mutants |
| 01/28/1992 | US5084396 Monoclonal antibodies absorbed onto a matrix and binding, mixing with a polyvalent antigen to form an immune complex, immunizing animals, fusion spleen cells to form hybridomas and culturing |
| 01/28/1992 | US5084391 Monoclonal antibody to the interleukin-2-receptor and its use |
| 01/28/1992 | US5084271 Vaccine for equine herpesvirus |
| 01/28/1992 | US5084269 Adjuvant for dose treatment with antigens |
| 01/28/1992 | CA2088162A1 Peptides and pharmaceutical compositions having glycoprotein hormone agonistic or antagonistic activity |
| 01/28/1992 | CA1294901C Monoclonal antibody specific for human colon fibroblast-derived t-pa |
| 01/26/1992 | WO1992001787A1 Binding domains |
| 01/26/1992 | CA2087095A1 Binding domains |
| 01/25/1992 | WO1992001469A1 A composition providing improved clearance of bioactive substances from the bloodstream |
| 01/25/1992 | CA2087971A1 Composition providing improved clearance of bioactive substances from the bloodstream |
| 01/25/1992 | CA2047585A1 Herpesvirus-based viral vector which expresses a foot and mouth disease virus epitope on the surface of virus-infected cells and on the surface of virus particles, and vaccine against foot and mouth disease containing the same |
| 01/24/1992 | CA2047618A1 Use of particular compounds for manufacture of pharmaceutical formulations for metabolic treatments |
| 01/23/1992 | WO1992001059A1 Cdr grafted anti-cea antibodies and their production |
| 01/23/1992 | WO1992001057A1 Ehv-4 glycoprotein vaccine |
| 01/23/1992 | WO1992001049A2 Cd53 cell surface antigen and use thereof |
| 01/23/1992 | WO1992001045A1 Equine herpesvirus-4 tk- vaccine |
| 01/23/1992 | WO1992001044A1 Mouse/human heterohybrid cell line el41 and methods for the production of human monoclonal antibodies |
| 01/23/1992 | WO1992001000A1 Basophil granule proteins |
| 01/23/1992 | WO1992000997A1 Synthetic peptides and mixtures thereof for detecting hiv antibodies |
| 01/23/1992 | WO1992000987A1 Primate lentivirus vaccines |
| 01/23/1992 | WO1992000757A1 Diagnosis of metastatic cancer by the mts-1 gene |
| 01/23/1992 | WO1992000756A1 Immune suppressive product |
| 01/23/1992 | CA2086932A1 Basophil granule proteins |
| 01/23/1992 | CA2086829A1 Diagnosis of metastatic cancer by the mts-1 gene |
| 01/23/1992 | CA2086740A1 Equine herpesvirus-4 tk-vaccine |
| 01/23/1992 | CA2086739A1 Ehv-4 glycoprotein vaccine |
| 01/22/1992 | EP0467839A1 In vitro processing of fusion proteins |
| 01/22/1992 | EP0467714A1 The class II protein of the outer membrane of neisseria meningitidis |
| 01/22/1992 | EP0467701A2 Cyclic HIV principal neutralizing determinant peptides |
| 01/22/1992 | EP0467700A2 Coconjugate vaccines comprising immunogenic protein, HIV related peptides, and anionic moieties |
| 01/22/1992 | EP0467699A2 Cyclic HIV principal neutralizing determinant peptides |
| 01/22/1992 | EP0467416A1 Antibody compositions of therapeutic agents having an extended serum half-life |
| 01/22/1992 | EP0466838A1 Novel lipid a derivatives and uses therefor |
| 01/22/1992 | EP0466813A1 Active specific immunotherapy of adenocarcinomas producing immunosuppressive mucins |
| 01/22/1992 | CN1058044A Method of preparing plasmid having both expressing ability of retrovial gene and processing ability after translation, and resultant plasmid and expression products thereof |
| 01/21/1992 | WO1992001474A1 Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures |
| 01/21/1992 | US5082927 Genetic engineering, immunology |
| 01/21/1992 | US5082776 Method of producing an adult t cell leukemia virus fused antigen polypeptide |
| 01/21/1992 | CA2087163A1 Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures |
| 01/20/1992 | WO1992001472A1 Multivalent anti-cytokine immunoglobulins |
| 01/20/1992 | WO1992001464A1 Inhibition of mac-1 receptor binding to fibrinogen using d30 homologs |
| 01/20/1992 | WO1992001461A1 Asphodelus composition for increasing white blood cell count |
| 01/20/1992 | CA2087541A1 Multivalent anti-cytokine immunoglobulins |
| 01/20/1992 | CA2087169A1 Inhibition of mac-1 receptor binding to fibrinogen using d30 homologs |
| 01/20/1992 | CA2086933A1 Asphodelus composition for increasing white blood cell count |
| 01/20/1992 | CA2050635A1 Class ii protein of the outer membrane of neisseria meningitidis having immunologic carrier and enhancement properties, and vaccines containing same |
| 01/20/1992 | CA2047078A1 Cyclic hiv principal neutralizing determinant peptides |
| 01/20/1992 | CA2047073A1 Coconjugate vaccines comprising immunogenic protein, hiv related peptides, and anionic moieties |
| 01/20/1992 | CA2047043A1 Class ii protein of the outer membrane of neisseria meningitidis having immune enhancement properties |
| 01/20/1992 | CA2047042A1 Cyclic hiv principal neutralizing determinant peptides |
| 01/20/1992 | CA2047033A1 Cyclic hiv principal neutralizing determinant peptides |
| 01/20/1992 | CA2047031A1 Peptide-polysaccharide-protein conjugate vaccines |
| 01/20/1992 | CA2047030A1 Class ii protein of the outer membrane of neisseria meningitidis having immunologic carrier and enhancement properties |
| 01/19/1992 | WO1992001475A1 Compositions based on active principles of hydrophobic medicaments solubilizable in an aqueous solvent |
| 01/19/1992 | CA2087536A1 Compositions based on active ingredients of hydrophobic drugs that can be sulubilized in an aqueous solvent |
| 01/19/1992 | CA2047041A1 Process for purification of hepatitis-a virus capsids |
| 01/17/1992 | WO1992001797A1 IMMUNOGLOBULIN PRODUCTION BY $i(TRICHODERMA) |
| 01/17/1992 | CA2084189A1 Immunoglobulin production by trichoderma |
| 01/17/1992 | CA2045842A1 Dna capable of site-specific integration into mycobacteria |